Shares of Collegium Pharmaceutical Inc. (NASDAQ:COLL) were down 4.3% on Wednesday . The stock traded as low as $8.60 and last traded at $8.60, with a volume of 81,063 shares traded. The stock had previously closed at $8.99.

Several analysts have recently weighed in on COLL shares. Needham & Company LLC reissued a “buy” rating and set a $30.00 price objective (up previously from $28.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. Piper Jaffray Cos. reissued a “buy” rating and set a $27.00 price objective (up previously from $26.00) on shares of Collegium Pharmaceutical in a report on Thursday, June 23rd. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Collegium Pharmaceutical has an average rating of “Buy” and a consensus price target of $28.25.

The company’s market cap is $207.75 million. The company’s 50 day moving average is $11.37 and its 200 day moving average is $15.34.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.29. On average, equities research analysts forecast that Collegium Pharmaceutical Inc. will post ($3.88) earnings per share for the current year.

In other Collegium Pharmaceutical news, Director John A. Fallon acquired 2,375 shares of the company’s stock in a transaction on Friday, August 12th. The shares were purchased at an average price of $10.59 per share, for a total transaction of $25,151.25. Following the completion of the purchase, the director now directly owns 2,375 shares of the company’s stock, valued at $25,151.25. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.